MTA Ancillary Agreement: Duke Limited Ancillary Agreement for dCas9

Please consult the UBMTA for definitions of MATERIAL, RECIPIENT and RECIPIENT SCIENTIST regarding this transfer of the MATERIAL.

By agreeing to this Ancillary Agreement, the RECIPIENT and RECIPIENT SCIENTIST acknowledge the following:

Duke University (“DUKE”) is the owner of certain dCas9 plasmids (“PATENTED MATERIAL”), and retains ownership rights to PATENTED MATERIAL incorporated in any derivative materials made by the RECIPIENT. PATENTED MATERIAL is covered by certain issued patents and/or pending patents owned by DUKE. DUKE holds the exclusive commercial distribution rights to such PATENTED MATERIAL deposited with Addgene. All uses of PATENTED MATERIAL, other than for research by a non-commercial or academic entity, require a license and use authorization from DUKE. Further transfer of this material by RECIPIENT is prohibited.

The distribution of the PATENTED MATERIAL by Addgene is not meant to carry with it, and does not grant any license, express or implied, under any patent.

In the event of any conflict between this Ancillary Agreement and the UBMTA, this Ancillary Agreement shall take precedence.